Elevated Rates Of Obesity And Heart Disease Fuel Expansion Of The Type 2 Diabetes Market Continues To Impact The Growth Of The Type 2 Diabetes Market

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Growth In Market Size Of The Type 2 Diabetes Market During 2026–2030?

The type 2 diabetes market has shown significant expansion in recent years. It is anticipated to increase from $51.47 billion in 2025 to $55.53 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.9%. Historically, this market’s growth can be linked to factors like the escalating global obesity rates, the rise in sedentary behaviors, broader access to oral antidiabetic drugs, increased screening for metabolic disorders, and improved provision of primary diabetes care.

The type 2 diabetes market is projected to experience substantial expansion in the coming years, anticipated to reach $78.67 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.1%. This growth during the forecast period is primarily driven by factors such as a heightened demand for therapies centered on weight management, a surge in the adoption of individualized diabetes treatment strategies, the broadening of digital therapeutic platforms, an intensified focus on proactive diabetes prevention, and increased capital flow into innovative antidiabetic medications. Key trends emerging in this period encompass the growing uptake of GLP-1 receptor agonists, an increased emphasis on managing cardiometabolic risks, the expanding utilization of multi-drug therapies, the development of treatment methods that integrate lifestyle changes, and a stronger commitment to achieving sustained glycemic control.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13050&type=smp

Which Strategic Drivers Are Supporting The Type 2 Diabetes Market Development?

The forward trajectory of the type 2 diabetes market is anticipated to be driven by escalating incidences of obesity and heart disease. Obesity is defined as a medical state where an unhealthy accumulation of excess body fat occurs, whereas heart disease encompasses various ailments impacting the heart and its associated blood vessels. Elevated body weight raises the likelihood of insulin resistance, which in turn results in elevated blood sugar and the onset of type 2 diabetes. Conversely, high blood glucose concentrations can harm the blood vessels and nerves vital for cardiac and circulatory function, culminating in heart disease. As an illustration, in March 2024, the World Health Organization (WHO), an intergovernmental entity situated in Switzerland, disclosed that roughly one in eight individuals globally contended with obesity. This figure comprised 2.5 billion adults (18 years and older) who were categorized as overweight, with 890 million of these individuals experiencing obesity. Among the adult demographic, 43% were overweight, and 16% were identified as obese. Furthermore, the population of overweight children under the age of 5 reached 37 million. Consequently, the escalating prevalence of obesity and heart disease is fueling the expansion of the type 2 diabetes market.

How Is The Type 2 Diabetes Market Structured Across Different Market Segments?

The type 2 diabetes market covered in this report is segmented –

1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Sulfonylureas And Insulin Secretagogues, Biguanides, SodiumGlucose Cotransporter 2 Inhibitors, Other Drug Classes

2) By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Other Applications

3) By End-User: Children, Adults

Subsegments:

1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide, Semaglutide, Dulaglutide, Exenatide

3) By Thiazolidinediones: Pioglitazone, Rosiglitazone

4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol

5) By Sulfonylureas And Insulin Secretagogues: Glimepiride, Glipizide, Glyburide

6) By Biguanides: Metformin, Buformin, Phenformin

7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

8) By Other Drug Classes: Amylin Analogues, Bile Acid Sequestrants, Dopamine Agonists

Which Trends Are Expected To Shape The Type 2 Diabetes Market?

Leading companies within the type 1 diabetes market are prioritizing the creation of advanced therapeutic solutions, such as allogeneic islet cell transplantation, aiming to provide functional beta-cell replacement and diminish insulin reliance for type 1 diabetes patients. Allogeneic islet cell transplantation is defined as the introduction of donor pancreatic islet cells into a patient’s hepatic portal vein, with the goal of re-establishing internal insulin production and decreasing the occurrence of hypoglycemic incidents and insulin injections. For example, in June 2023, CellTrans Inc., a US-based biotechnology firm, obtained clearance from the U.S. Food and Drug Administration (FDA) for Lantidra (donislecel), marking it as the first cellular therapy specifically for type 1 diabetes patients. This approval signifies a major breakthrough in regenerative medicine, presenting a possible enduring treatment alternative for individuals with type 1 diabetes who contend with insulin dependence. Lantidra operates by substituting the insulin-producing cells eradicated by the immune system, thereby striving to reinstate the body’s inherent capacity to manage blood glucose levels.

Which Companies Are Engaged In The Type 2 Diabetes Market Environment?

Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc, Novartis AG, AstraZeneca plc, Abbott Laboratories, Sanofi SA, Medtronic plc, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd, Boehringer Ingelheim International GmbH, Dexcom Inc, Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health

Access The Complete Type 2 Diabetes Market Report:

https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

What Is The Largest Regional Market In The Type 2 Diabetes Market?

North America was the largest region in the type 2 diabetes market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the type 2 diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Type 2 Diabetes Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=13050&type=smp

Browse Through More Reports Similar to the Global Type 2 Diabetes Market 2026, By The Business Research Company

Type 1 Diabetes Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/type-1-diabetes-global-market-report

Antidiabetics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Diabetes Care Devices Market 2026

https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795